Product image of Linagliptine Viatris (Linagliptin) supplied by GNH India

Linagliptine Viatris

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptine Viatris (Linagliptin)

Linagliptin, the active ingredient in Linagliptine Viatris, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adult patients.

GNH India supplies Linagliptine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptine Viatris is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. It helps lower blood glucose levels when combined with lifestyle measures.

  • Type 2 diabetes mellitus: improves glycaemic control as an adjunct to diet and exercise.
  • Monotherapy in type 2 diabetes: provides glucose‑lowering effect when other oral agents are unsuitable.
  • Combination therapy: can be added to metformin, sulfonylureas or insulin to enhance overall glucose control.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 enzyme, preventing the breakdown of incretin hormones GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in reduced hepatic glucose production and improved post‑prandial glucose regulation.

Side Effects

Linagliptine Viatris is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract infection.
  • Headache: transient mild to moderate pain.
  • Upper respiratory infection: cough, sore throat.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal upset: nausea, abdominal discomfort.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring medical attention.
  • Severe allergic reactions: angioedema, rash, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Severe hypoglycaemia: when combined with insulin or sulfonylureas.
  • Bullous pemphigoid: rare skin blistering disorder.

Precautions & Warnings

When prescribing Linagliptine Viatris, clinicians should consider several safety aspects.

  • Renal impairment: monitor renal function; dose adjustment generally not required but caution advised.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Cardiovascular disease: observe for any worsening of heart failure symptoms.
  • Pregnancy: safety not established; avoid unless benefit outweighs risk.
  • Breastfeeding: unknown safety; consider alternative therapy.
  • Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Avoid Interactions

Linagliptine Viatris may interact with other medicines; awareness of interaction severity helps guide therapy.

Major Interactions (Avoid)

  • Concomitant use with other DPP‑4 inhibitors: additive effect, risk of excessive inhibition.
  • Combination with insulin or sulfonylureas: increased risk of hypoglycaemia.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure.

Moderate Interactions (Monitor Closely):\n- Diuretics: monitor electrolytes and renal function.

  • ACE inhibitors or ARBs: watch for hypotension.
  • NSAIDs: assess renal function when used together.
  • Anticoagulants: observe for any changes in bleeding risk.
  • Antihypertensives: monitor blood pressure for additive effects.

Frequently Asked Questions

Linagliptine Viatris contains the active ingredient linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It is used as an adjunct to diet and exercise to improve blood glucose control in adult patients.

Linagliptin selectively blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion, reduces glucagon release, and lowers hepatic glucose production, leading to better glycaemic control.

The specific dose of Linagliptine Viatris is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Linagliptine Viatris, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which differs from sulfonylureas, metformin, or SGLT‑2 inhibitors in its mechanism of enhancing endogenous incretin activity rather than directly stimulating insulin release or reducing glucose reabsorption. It generally has a low risk of hypoglycaemia when used as monotherapy and does not require dose adjustment in renal impairment.

Linagliptine Viatris should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and discard any product that appears damaged or discoloured.

Linagliptine Viatris is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare professional.

Serious risks, although rare, include pancreatitis, severe allergic reactions such as angioedema, hepatic injury, and bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling of the face or throat, or unexplained jaundice.

Linagliptine Viatris is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. It should also be avoided in individuals with a history of severe pancreatitis or those taking other DPP‑4 inhibitors concurrently.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT